Malik Sheza, Loganathan Priyadarshini, Khan Hajra, Shadali Abul Hasan, Yarra Pradeep, Chandan Saurabh, Mohan Babu P, Adler Douglas G, Kothari Shivangi
Department of Internal Medicine, Rochester General Hospital, Rochester, NY, USA.
Department of Internal Medicine, UT Health, San Antonio, TX, USA.
Clin Endosc. 2025 Mar;58(2):240-252. doi: 10.5946/ce.2024.120. Epub 2025 Feb 3.
BACKGROUND/AIMS: Self-expanding metallic stents (SEMS) are an alternative to emergency surgery (ES) for malignant colorectal obstruction. This study aimed to compare surgical outcomes between SEMS as a bridge to surgery (BTS) and ES in patients with malignant colorectal obstruction.
A comprehensive database search was conducted until October 2023 to compare outcomes between SEMS as a BTS and ES. A subgroup analysis of results by malignancy site was performed.
We analyzed 57 studies, including 7,223 patients over a mean duration of 35.4 months. SEMS as a BTS showed clinical and technical success rates of 88.0% (95% confidence interval [CI], 86.1%-90.1%; I2=68%) and 91.6% (95% CI, 89.7%-93.7%; I2=66%), respectively. SEMS as a BTS revealed reduced postoperative adverse events (odds ratio [OR], 0.51; 95% CI, 0.41-0.63; I2=70%; p<0.001) and 30-day mortality (OR, 0.52; 95% CI, 0.37-0.72; I2=10%; p<0.001) compared to ES. Subgroup analysis showed postoperative mortality of 5% and 1.5% for left- and right-sided malignancies, respectively. Adverse events were 15% and 33% for the right and left colon, respectively.
SEMS as a BTS demonstrated a higher success rate, fewer postoperative adverse events, and a reduced 30-day mortality rate than ES, supporting its use as the preferred initial intervention for right- and left-sided obstructions and indicating broader clinical adoption.
背景/目的:自膨式金属支架(SEMS)是治疗恶性结直肠梗阻的紧急手术(ES)的一种替代方法。本研究旨在比较SEMS作为手术桥梁(BTS)与ES治疗恶性结直肠梗阻患者的手术结局。
进行全面的数据库检索,直至2023年10月,以比较SEMS作为BTS与ES的结局。对恶性肿瘤部位的结果进行亚组分析。
我们分析了57项研究,包括7223例患者,平均随访时间为35.4个月。SEMS作为BTS的临床成功率和技术成功率分别为88.0%(95%置信区间[CI],86.1%-90.1%;I2=68%)和91.6%(95%CI,89.7%-93.7%;I2=66%)。与ES相比,SEMS作为BTS术后不良事件(优势比[OR],0.51;95%CI,0.41-0.63;I2=70%;p<0.001)和30天死亡率(OR,0.52;95%CI,0.37-0.72;I2=10%;p<0.001)均降低。亚组分析显示,左侧和右侧恶性肿瘤的术后死亡率分别为5%和1.5%。右侧和左侧结肠的不良事件分别为15%和33%。
SEMS作为BTS比ES具有更高的成功率、更少的术后不良事件和更低的30天死亡率,支持将其作为左右侧梗阻的首选初始干预措施,并表明其在临床上有更广泛的应用。